CORS is a cross- faculty university anchored institution involving various public (Danish Medicines Agency, Copenhagen University) and private stakeholders (Novo Nordisk, Lundbeck, Ferring pharmaceuticals, LEO pharma) as well as patient organisations (Rare Diseases Denmark).

The centre is purely devoted to the scientific aspects of the regulatory field and with a patient- oriented focus and the research is not company- specific product or directly company related.